Elisabeth M C Dequeker
Overview
Explore the profile of Elisabeth M C Dequeker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ly A, Garcia V, Blenman K, Ehinger A, Elfer K, Hanna M, et al.
Histopathology
. 2024 Mar;
84(6):915-923.
PMID: 38433289
A growing body of research supports stromal tumour-infiltrating lymphocyte (TIL) density in breast cancer to be a robust prognostic and predicive biomarker. The gold standard for stromal TIL density quantitation...
2.
Laudus N, Nijs L, Nauwelaers I, Dequeker E
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954349
External quality assessment (EQA) schemes are a tool for clinical laboratories to evaluate and manage the quality of laboratory practice with the support of an independent party (i.e., an EQA...
3.
Fairley J, Cheetham M, Patton S, Rouleau E, Denis M, Dequeker E, et al.
BMC Cancer
. 2022 Jul;
22(1):759.
PMID: 35820813
Background: Circulating cell free DNA (cfDNA) testing of plasma for EGFR somatic variants in lung cancer patients is being widely implemented and with any new service, external quality assessment (EQA)...
4.
Keppens C, Boone E, Gameiro P, Tack V, Moreau E, Hodges E, et al.
Virchows Arch
. 2021 Mar;
479(2):365-376.
PMID: 33686511
Clonality analysis of immunoglobulin (IG) or T-cell receptor (TR) gene rearrangements is routine practice to assist diagnosis of lymphoid malignancies. Participation in external quality assessment (EQA) aids laboratories in identifying...
5.
Keppens C, Schuuring E, Dequeker E
Virchows Arch
. 2020 Nov;
478(5):995-1006.
PMID: 33225398
External quality assessment (EQA) schemes assess the performance of predictive biomarker testing in lung and colorectal cancer and have previously demonstrated variable error rates. No information is currently available on...
6.
de Wert G, Dondorp W, Clarke A, Dequeker E, Cordier C, Deans Z, et al.
Eur J Hum Genet
. 2020 Nov;
29(3):365-377.
PMID: 33223530
If genome sequencing is performed in health care, in theory the opportunity arises to take a further look at the data: opportunistic genomic screening (OGS). The European Society of Human...
7.
Dufraing K, Fenizia F, Torlakovic E, Wolstenholme N, Deans Z, Rouleau E, et al.
Virchows Arch
. 2020 Oct;
478(3):553-565.
PMID: 33047156
In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to ensure accurate results is participation...
8.
Keppens C, Von Der Thusen J, Pauwels P, Ryska A, t Hart N, Schuuring E, et al.
J Mol Diagn
. 2020 Oct;
22(12):1438-1452.
PMID: 33011443
Selection of non-small-cell lung cancer patients for treatment relies on the detection of expression of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) protein by immunohistochemistry (IHC). We evaluated...
9.
Vermeersch P, Van Aelst T, Dequeker E
Clin Chem Lab Med
. 2020 Jul;
59(1):101-106.
PMID: 32692695
Objectives: The new European In Vitro Diagnostic (IVD) Regulation 2017/746 (IVDR) restricts the use of lab-developed tests (LDT) after 26th May 2022. There are no data on the impact of...
10.
Laudus N, Audrezet M, Girodon E, Morris M, Radojkovic D, Raynal C, et al.
J Cyst Fibros
. 2020 Jun;
19(6):969-974.
PMID: 32505523
Background: The clinical spectrum associated with cystic fibrosis transmembrane conductance regulator (CFTR) variant p.Arg117His is highly variable, ranging from full-blown cystic fibrosis (CF) in a small number of cases to...